Amgen Inc. (NASDAQ: AMGN), whose bone pain drug, Xgeva, failed to get an FDA panel’s approval for use as a treatment for prostate cancer, is most often mentioned as a potential suitor for Dendreon. Dendreon’s market cap of around $1.5 billion is well within Amgen’s scope.
Dendreon’s shares are up more than 4.5% at $10.39 in a 52-week range of $6.46-$43.96.
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
